Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Knigge

Showing results (51-60 of 108) with videos related to

Pageof 11
Sort By:
Neuroendocrinology|October 3, 2019
Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine TumorsGitte Dam, Henning Grønbæk, Halfdan Sorbye, et al.
Acta Oncologica (Stockholm, Sweden)|May 28, 2011
First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experienceIngrid Holst Olsen, Seppo W Langer, Ida Jepsen, et al.
Journal of Neuroendocrinology|March 19, 2026
Follow-up is not justified in patients with typical lung carcinoids without lymph node involvement treated with curative intent: A Danish Multi-ENETS Center of Excellence StudyTobias Stemann Lau, Patrick Soldath, Karina Stubkjær Rewitz, et al.
Cancers|April 13, 2024
Effects of Peptide Receptor Radiotherapy in Patients with Advanced Paraganglioma and Pheochromocytoma: A Nation-Wide Cohort StudyLinda Skibsted Kornerup, Mikkel Andreassen, Ulrich Knigge, et al.
Journal of Neuroendocrinology|September 8, 2023
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for appendiceal neuroendocrine tumours (aNET)Gregory Kaltsas, Thomas Walter, Ulrich Knigge, et al.
Journal of Neuroendocrinology|July 13, 2022
Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumorsEspen Thiis-Evensen, Magnus Kjellman, Ulrich Knigge, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 27, 2021
Semiautomatic Tumor Delineation for Evaluation of <sup>64</sup>Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor VolumeEsben Andreas Carlsen, Camilla Bardram Johnbeck, Mathias Loft, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 24, 2016
Head-to-Head Comparison of <sup>64</sup>Cu-DOTATATE and <sup>68</sup>Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine TumorsCamilla B Johnbeck, Ulrich Knigge, Annika Loft, et al.
Neuroendocrinology|February 22, 2011
Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in SwitzerlandAndreas Klaus Pfeifer, Tine Gregersen, Henning Grønbæk, et al.
Genes|December 30, 2014
Down-Regulation of miR-129-5p and the let-7 Family in Neuroendocrine Tumors and Metastases Leads to Up-Regulation of Their Targets Egr1, G3bp1, Hmga2 and Bach1Kristina B V Døssing, Tina Binderup, Bogumil Kaczkowski, et al.
Pageof 11

Showing results (51-60 of 108) with videos related to

Sort By:
Pageof 11
Neuroendocrinology|October 3, 2019
Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine TumorsGitte Dam, Henning Grønbæk, Halfdan Sorbye, et al.
Acta Oncologica (Stockholm, Sweden)|May 28, 2011
First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experienceIngrid Holst Olsen, Seppo W Langer, Ida Jepsen, et al.
Journal of Neuroendocrinology|March 19, 2026
Follow-up is not justified in patients with typical lung carcinoids without lymph node involvement treated with curative intent: A Danish Multi-ENETS Center of Excellence StudyTobias Stemann Lau, Patrick Soldath, Karina Stubkjær Rewitz, et al.
Cancers|April 13, 2024
Effects of Peptide Receptor Radiotherapy in Patients with Advanced Paraganglioma and Pheochromocytoma: A Nation-Wide Cohort StudyLinda Skibsted Kornerup, Mikkel Andreassen, Ulrich Knigge, et al.
Journal of Neuroendocrinology|September 8, 2023
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for appendiceal neuroendocrine tumours (aNET)Gregory Kaltsas, Thomas Walter, Ulrich Knigge, et al.
Journal of Neuroendocrinology|July 13, 2022
Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumorsEspen Thiis-Evensen, Magnus Kjellman, Ulrich Knigge, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 27, 2021
Semiautomatic Tumor Delineation for Evaluation of <sup>64</sup>Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor VolumeEsben Andreas Carlsen, Camilla Bardram Johnbeck, Mathias Loft, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 24, 2016
Head-to-Head Comparison of <sup>64</sup>Cu-DOTATATE and <sup>68</sup>Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine TumorsCamilla B Johnbeck, Ulrich Knigge, Annika Loft, et al.
Neuroendocrinology|February 22, 2011
Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in SwitzerlandAndreas Klaus Pfeifer, Tine Gregersen, Henning Grønbæk, et al.
Genes|December 30, 2014
Down-Regulation of miR-129-5p and the let-7 Family in Neuroendocrine Tumors and Metastases Leads to Up-Regulation of Their Targets Egr1, G3bp1, Hmga2 and Bach1Kristina B V Døssing, Tina Binderup, Bogumil Kaczkowski, et al.
Pageof 11